Larger trial sizes reduce statistical errors
The guest argued that larger clinical trial enrollments inherently lower both Type I and Type II error rates, preventing viable drugs from being prematurely abandoned due to statistical noise.
The argument
China's massive population and streamlined enrollment processes allow for larger average trial sizes. This reduces false positives and false negatives, whereas smaller US trials are more prone to statistical failures that lead to drug abandonment.
The thesis, stress-tested
✓ What validates it
- —
▸ Risks discussed
- ▸High cost of maintaining large sample sizes
- ▸Potential dilution of patient-specific efficacy signals in overly broad cohorts